Competition Law for the Pharma Sector
|Event Date/Time: Jun 09, 2003||End Date/Time: Jun 10, 2003|
9-10 June 2003 * Hilton London Green Park Hotel, London W1
The Advocate General’s opinion on the Bayer/Adalat case will be released by the time of the conference. This event is perfectly timed to inform delegates of the effect of the case on pharmaceutical pricing.
This year has seen an unprecedented number of developments in competition law both in the UK and at EU level. With the pharma sector already under the regulator’s spotlight following recent investigations and high profile cases, many of these developments will have a huge impact on the pharma industry.
At this critical time, and considering the stakes involved, pharma companies and their legal advisors must have an up-to-the-minute understanding of how to respond to these challenging issues.
EuroLegal has brought together an outstanding panel of speakers including senior representatives of the OFT and leading legal advisors to the key pharma players.
Hear from these experts and leading advisers to the key industry players:
Competition Enforcement Division, OFT * Mergers Division, OFT * Schering-Plough *
Arnold & Porter * Bristows * Europe Economics * Bird & Bird * Taylor Wessing *
CMS Cameron McKenna * Nabarro Nathanson * McDermott Will & Emery
Issues they will cover include:
Ø The new Bayer/Adalat decision: where do you stand now? Practical advice to take your distribution strategy forward.
Ø How the OFT Competition Enforcement Division carried out its analysis of the pharma market in the Napp Pharmaceuticals case
Ø OFT Mergers Division’s perspective on what the substantial lessening of competition test really means for pharma companies
Ø The lessons of Napp Pharmaceuticals in respect of product pricing and abuse of a dominant position
This conference qualifies for 11 CPD hours
To register or for more information call Jacqueline Gorman on +44 (0) 20 7878 6907 or visit the conference website: www.euro-legal.co.uk/comppharm/pr